 |
市场调查报告书
商品编码
1457981
全球来那度胺市场研究报告 - 2024 年至 2032 年产业分析、规模、份额、成长、趋势与预测Global Lenalidomide Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032 |
||||||
全球来那度胺市场需求预计将从2023年的182.3亿美元达到近313亿美元的市场规模，2024-2032年研究期间CAGR为6.19%。
来那度胺是一种用于治疗某些癌症的药物，特别是多发性骨髓瘤和骨髓增生异常综合症。它属于一类被称为免疫调节剂的药物，致力于改变免疫系统的反应并抑制癌细胞的生长。来那度胺通常与其他疗法合併使用以提高疗效。
市场动态
在血液系统恶性肿瘤，特别是多发性骨髓瘤和骨髓增生异常综合症盛行率不断扩大的推动下，来那度胺市场正在显着增长。来那度胺是一种免疫调节药物，已证明可以有效治疗这些疾病，从而在临床环境中得到越来越多的采用。此外，正在进行的研究和开发活动探索该药物治疗各种癌症的潜力，有助于其市场扩张。此外，有利的报销政策和对该药物治疗益处的日益认识促进了市场成长。全球人口老化是与这些血液疾病相关的重要人口因素，进一步推动了对这种药物的需求。然而，某些因素，例如严格的监管要求和潜在的不利副作用，可能会阻碍来那度胺市场。
研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具还对来那度胺全球市场的每个细分市场进行了包容性评估。来那度胺产业的成长和趋势为本研究提供了整体方法。
市场区隔
来那度胺市场报告的这一部分提供了国家和区域层面细分市场的详细资料，从而帮助策略师确定相应产品或服务的目标人群以及即将到来的机会。
按类型
- 5毫克胶囊
- 10毫克胶囊
- 15毫克胶囊
- 25毫克胶囊
按申请
- 多发性骨髓瘤 (MM)
- 骨髓增生异常症候群 (MDS)
- 其他应用
按最终用户
- 医院
- 癌症治疗中心
- 研究机构
区域分析
本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲来那度胺市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。
- 全球来那度胺市场份额（按地区）（代表图）
- 全球来那度胺市场份额
该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。来那度胺市场的主要参与者包括Accord Healthcare、Cipla、Deva Pharma、Dr. Reddy's Laboratories Ltd.、Glenmark Pharmaceuticals、Hetero、Hikma Pharmaceuticals、Lupin Limited、Sun Pharmaceutical Industries Ltd.、Teva Pharmaceutical Industries Ltd.、Torrent Pharmaceuticals Ltd.。 ，Viatris Inc.。本部分包含竞争格局的整体视图，包括各种策略发展，例如关键併购、未来产能、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。
如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。
目录
第一章：前言
- 报告说明
- 客观的
- 目标受众
- 独特的销售主张 (USP) 和产品
- 研究范围
- 研究方法论
- 市场研究过程
- 市场研究方法论
第 2 章：执行摘要
- 市集亮点
- 全球市场概况
第 3 章：来那度胺 - 产业分析
- 简介 - 市场动态
- 市场驱动因素
- 市场限制
- 机会
- 产业动态
- 波特五力分析
- 市场吸引力分析
- 按类型分類的市场吸引力分析
- 市场吸引力分析：依应用分类
- 最终用户的市场吸引力分析
- 市场吸引力分析：按地区
第 4 章：价值链分析
- 价值链分析
- 原料分析
- 原料清单
- 原料厂商清单
- 主要原物料价格走势
- 潜在买家名单
- 行销管道
- 直效行销
- 间接行销
- 行销通路发展趋势
第 5 章：全球来那度胺市场分析：按类型
- 按类型概述
- 历史和预测数据
- 按类型分析
- 5毫克胶囊
- 10毫克胶囊
- 15毫克胶囊
- 25毫克胶囊
第 6 章：全球来那度胺市场分析：依应用分类
- 概述：按应用
- 历史和预测数据
- 分析：按应用
- 多发性骨髓瘤 (MM)
- 骨髓增生异常症候群 (MDS)
- 其他应用
第 7 章：全球来那度胺市场分析：依最终使用者分类
- 最终用户概述
- 历史和预测数据
- 最终用户分析
- 医院
- 癌症治疗中心
- 研究机构
第 8 章：全球来那度胺市场分析：依地理位置
- 区域展望
- 介绍
- 北美销售分析
- 概览、历史与预测资料销售分析
- 北美按细分市场销售分析
- 北美按国家销售分析
- 美国销售分析
- 加拿大销售分析
- 墨西哥销售分析
- 欧洲销售分析
- 概览、历史与预测资料销售分析
- 欧洲按细分市场销售分析
- 欧洲按国家销售分析
- 英国销售分析
- 法国销售分析
- 德国销售分析
- 义大利销售分析
- 俄罗斯销售分析
- 欧洲其他地区销售分析
- 亚太地区销售分析
- 概览、历史与预测资料销售分析
- 亚太地区按细分市场销售分析
- 亚太地区国家/地区销售分析
- 中国销售分析
- 印度销售分析
- 日本销售分析
- 韩国销售分析
- 澳洲销售分析
- 东南亚销售分析
- 亚太地区其他地区销售分析
- 拉丁美洲销售分析
- 概览、历史与预测资料销售分析
- 拉丁美洲按细分市场销售分析
- 拉丁美洲按国家销售分析
- 巴西销售分析
- 阿根廷销售分析
- 秘鲁销售分析
- 智利销售分析
- 拉丁美洲其他地区销售分析
- 中东和非洲销售分析
- 概览、历史与预测资料销售分析
- 中东和非洲按细分市场销售分析
- 中东和非洲国家销售分析
- 沙乌地阿拉伯销售分析
- 阿联酋销售分析
- 以色列销售分析
- 南非销售分析
- 中东其他地区和非洲销售分析
第 9 章：来那度胺公司的竞争格局
- 来那度胺市场竞争
- 伙伴关係/协作/协议
- 併购
- 新产品发布
- 其他发展
第 10 章：公司简介
- 公司股份分析
- 市场集中度
- Accord Healthcare
- 公司简介
- 公司收入
- 产品
- 最近的发展
- Cipla
- 公司简介
- 公司收入
- 产品
- 最近的发展
- Deva Pharma
- 公司简介
- 公司收入
- 产品
- 最近的发展
- Dr. Reddy's Laboratories Ltd.
- 公司简介
- 公司收入
- 产品
- 最近的发展
- Glenmark Pharmaceuticals
- 公司简介
- 公司收入
- 产品
- 最近的发展
- Hetero
- 公司简介
- 公司收入
- 产品
- 最近的发展
- Hikma Pharmaceuticals
- 公司简介
- 公司收入
- 产品
- 最近的发展
- Lupin Limited
- 公司简介
- 公司收入
- 产品
- 最近的发展
- Sun Pharmaceutical Industries Ltd.
- 公司简介
- 公司收入
- 产品
- 最近的发展
- Teva Pharmaceutical Industries Ltd.
- 公司简介
- 公司收入
- 产品
- 最近的发展
- Torrent Pharmaceuticals Ltd.
- 公司简介
- 公司收入
- 产品
- 最近的发展
- Viatris Inc.
- 公司简介
- 公司收入
- 产品
- 最近的发展
注意 - 在公司概况中，财务详细资讯和近期发展视情况而定，或者如果是私人公司，则可能不包括在内
The global demand for Lenalidomide Market is presumed to reach the market size of nearly USD 31.3 Billion by 2032 from USD 18.23 Billion in 2023 with a CAGR of 6.19% under the study period 2024 - 2032.
Lenalidomide is a medication used in the treatment of certain cancers, particularly multiple myeloma and myelodysplastic syndromes. It belongs to a class of drugs known as immunomodulatory agents, working to modify the immune system's response and inhibit the growth of cancer cells. lenalidomide is often prescribed in combination with other therapies for improved efficacy.
MARKET DYNAMICS
The lenalidomide market is witnessing significant growth, driven by the expanding prevalence of hematological malignancies, particularly multiple myeloma and myelodysplastic syndromes. Lenalidomide, an immunomodulatory drug, has demonstrated efficacy in treating these conditions, leading to increased adoption in clinical settings. Furthermore, ongoing research and development activities explore the drug's potential for treating various cancers, contributing to its market expansion. Additionally, favorable reimbursement policies and a growing awareness of the drug's therapeutic benefits foster market growth. The rise in aging populations globally, which is a significant demographic factor linked to these hematological disorders, is further fueling the demand for this medication. However, certain factors, such as stringent regulatory requirements and potential adverse side effects, will likely hamper the lenalidomide market.
The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of lenalidomide. The growth and trends of lenalidomide industry provide a holistic approach to this study.
MARKET SEGMENTATION
This section of the lenalidomide market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
By Type
- 5Mg Capsules
- 10Mg Capsules
- 15Mg Capsules
- 25Mg Capsules
By Application
- Multiple Myeloma (MM)
- Myelodysplastic Syndromes (MDS)
- Other Applications
By End-User
- Hospitals
- Cancer Treatment Centers
- Research Institutes
REGIONAL ANALYSIS
This section covers the regional outlook, which accentuates current and future demand for the Lenalidomide market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
- GLOBAL LENALIDOMIDE MARKET SHARE BY REGION (REPRESENTATIVE GRAPH)
- Global Lenalidomide Market Share
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Lenalidomide market include Accord Healthcare, Cipla, Deva Pharma, Dr. Reddy's Laboratories Ltd., Glenmark Pharmaceuticals, Hetero, Hikma Pharmaceuticals, Lupin Limited, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Viatris Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.
TABLE OF CONTENTS
1 . PREFACE
- 1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
- 1.2. Research Scope
- 1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology
2 . EXECUTIVE SUMMARY
- 2.1. Highlights of Market
- 2.2. Global Market Snapshot
3 . LENALIDOMIDE - INDUSTRY ANALYSIS
- 3.1. Introduction - Market Dynamics
- 3.2. Market Drivers
- 3.3. Market Restraints
- 3.4. Opportunities
- 3.5. Industry Trends
- 3.6. Porter's Five Force Analysis
- 3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Type
- 3.7.2 Market Attractiveness Analysis By Application
- 3.7.3 Market Attractiveness Analysis By End-User
- 3.7.4 Market Attractiveness Analysis By Region
4 . VALUE CHAIN ANALYSIS
- 4.1. Value Chain Analysis
- 4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
- 4.3. List of Potential Buyers
- 4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend
5 . GLOBAL LENALIDOMIDE MARKET ANALYSIS BY TYPE
- 5.1 Overview by Type
- 5.2 Historical and Forecast Data
- 5.3 Analysis by Type
- 5.4 5mg Capsules Historic and Forecast Sales by Regions
- 5.5 10mg Capsules Historic and Forecast Sales by Regions
- 5.6 15mg Capsules Historic and Forecast Sales by Regions
- 5.7 25mg Capsules Historic and Forecast Sales by Regions
6 . GLOBAL LENALIDOMIDE MARKET ANALYSIS BY APPLICATION
- 6.1 Overview by Application
- 6.2 Historical and Forecast Data
- 6.3 Analysis by Application
- 6.4 Multiple Myeloma (MM) Historic and Forecast Sales by Regions
- 6.5 Myelodysplastic Syndromes (MDS) Historic and Forecast Sales by Regions
- 6.6 Other Applications Historic and Forecast Sales by Regions
7 . GLOBAL LENALIDOMIDE MARKET ANALYSIS BY END-USER
- 7.1 Overview by End-User
- 7.2 Historical and Forecast Data
- 7.3 Analysis by End-User
- 7.4 Hospitals Historic and Forecast Sales by Regions
- 7.5 Cancer Treatment Centers Historic and Forecast Sales by Regions
- 7.6 Research Institutes Historic and Forecast Sales by Regions
8 . GLOBAL LENALIDOMIDE MARKET ANALYSIS BY GEOGRAPHY
- 8.1. Regional Outlook
- 8.2. Introduction
- 8.3. North America Sales Analysis
- 8.3.1. Overview, Historic and Forecast Data Sales Analysis
- 8.3.2. North America By Segment Sales Analysis
- 8.3.3. North America By Country Sales Analysis
- 8.3.4. United State Sales Analysis
- 8.3.5. Canada Sales Analysis
- 8.3.6. Mexico Sales Analysis
- 8.4. Europe Sales Analysis
- 8.4.1. Overview, Historic and Forecast Data Sales Analysis
- 8.4.2. Europe by Segment Sales Analysis
- 8.4.3. Europe by Country Sales Analysis
- 8.4.4. United Kingdom Sales Analysis
- 8.4.5. France Sales Analysis
- 8.4.6. Germany Sales Analysis
- 8.4.7. Italy Sales Analysis
- 8.4.8. Russia Sales Analysis
- 8.4.9. Rest Of Europe Sales Analysis
- 8.5. Asia Pacific Sales Analysis
- 8.5.1. Overview, Historic and Forecast Data Sales Analysis
- 8.5.2. Asia Pacific by Segment Sales Analysis
- 8.5.3. Asia Pacific by Country Sales Analysis
- 8.5.4. China Sales Analysis
- 8.5.5. India Sales Analysis
- 8.5.6. Japan Sales Analysis
- 8.5.7. South Korea Sales Analysis
- 8.5.8. Australia Sales Analysis
- 8.5.9. South East Asia Sales Analysis
- 8.5.10. Rest Of Asia Pacific Sales Analysis
- 8.6. Latin America Sales Analysis
- 8.6.1. Overview, Historic and Forecast Data Sales Analysis
- 8.6.2. Latin America by Segment Sales Analysis
- 8.6.3. Latin America by Country Sales Analysis
- 8.6.4. Brazil Sales Analysis
- 8.6.5. Argentina Sales Analysis
- 8.6.6. Peru Sales Analysis
- 8.6.7. Chile Sales Analysis
- 8.6.8. Rest of Latin America Sales Analysis
- 8.7. Middle East & Africa Sales Analysis
- 8.7.1. Overview, Historic and Forecast Data Sales Analysis
- 8.7.2. Middle East & Africa by Segment Sales Analysis
- 8.7.3. Middle East & Africa by Country Sales Analysis
- 8.7.4. Saudi Arabia Sales Analysis
- 8.7.5. UAE Sales Analysis
- 8.7.6. Israel Sales Analysis
- 8.7.7. South Africa Sales Analysis
- 8.7.8. Rest Of Middle East And Africa Sales Analysis
9 . COMPETITIVE LANDSCAPE OF THE LENALIDOMIDE COMPANIES
- 9.1. Lenalidomide Market Competition
- 9.2. Partnership/Collaboration/Agreement
- 9.3. Merger And Acquisitions
- 9.4. New Product Launch
- 9.5. Other Developments
10 . COMPANY PROFILES OF LENALIDOMIDE INDUSTRY
- 10.1. Company Share Analysis
- 10.2. Market Concentration Rate
- 10.3. Accord Healthcare
- 10.3.1. Company Overview
- 10.3.2. Company Revenue
- 10.3.3. Products
- 10.3.4. Recent Developments
- 10.4. Cipla
- 10.4.1. Company Overview
- 10.4.2. Company Revenue
- 10.4.3. Products
- 10.4.4. Recent Developments
- 10.5. Deva Pharma
- 10.5.1. Company Overview
- 10.5.2. Company Revenue
- 10.5.3. Products
- 10.5.4. Recent Developments
- 10.6. Dr. Reddy's Laboratories Ltd.
- 10.6.1. Company Overview
- 10.6.2. Company Revenue
- 10.6.3. Products
- 10.6.4. Recent Developments
- 10.7. Glenmark Pharmaceuticals
- 10.7.1. Company Overview
- 10.7.2. Company Revenue
- 10.7.3. Products
- 10.7.4. Recent Developments
- 10.8. Hetero
- 10.8.1. Company Overview
- 10.8.2. Company Revenue
- 10.8.3. Products
- 10.8.4. Recent Developments
- 10.9. Hikma Pharmaceuticals
- 10.9.1. Company Overview
- 10.9.2. Company Revenue
- 10.9.3. Products
- 10.9.4. Recent Developments
- 10.10. Lupin Limited
- 10.10.1. Company Overview
- 10.10.2. Company Revenue
- 10.10.3. Products
- 10.10.4. Recent Developments
- 10.11. Sun Pharmaceutical Industries Ltd.
- 10.11.1. Company Overview
- 10.11.2. Company Revenue
- 10.11.3. Products
- 10.11.4. Recent Developments
- 10.12. Teva Pharmaceutical Industries Ltd.
- 10.12.1. Company Overview
- 10.12.2. Company Revenue
- 10.12.3. Products
- 10.12.4. Recent Developments
- 10.13. Torrent Pharmaceuticals Ltd.
- 10.13.1. Company Overview
- 10.13.2. Company Revenue
- 10.13.3. Products
- 10.13.4. Recent Developments
- 10.14. Viatris Inc.
- 10.14.1. Company Overview
- 10.14.2. Company Revenue
- 10.14.3. Products
- 10.14.4. Recent Developments
Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies
LIST OF TABLES
- Market Snapshot
- Drivers : Impact Analysis
- Restraints : Impact Analysis
- List of Raw Material
- List of Raw Material Manufactures
- List of Potential Buyers
- Analysis by Type (USD MN)
- 5mg Capsules Market Sales by Geography (USD MN)
- 10mg Capsules Market Sales by Geography (USD MN)
- 15mg Capsules Market Sales by Geography (USD MN)
- 25mg Capsules Market Sales by Geography (USD MN)
- Analysis Market by Application (USD MN)
- Multiple Myeloma (MM) Market Sales by Geography (USD MN)
- Myelodysplastic Syndromes (MDS) Market Sales by Geography (USD MN)
- Other Applications Market Sales by Geography (USD MN)
- Analysis by End-User (USD MN)
- Hospitals Market Sales by Geography (USD MN)
- Cancer Treatment Centers Market Sales by Geography (USD MN)
- Research Institutes Market Sales by Geography (USD MN)
- Global Lenalidomide Market Sales by Geography (USD MN)
- North America Market Analysis (USD MN)
- United State Market Analysis (USD MN)
- Canada Market Analysis (USD MN)
- Mexico Market Analysis (USD MN)
- Europe Market Analysis (USD MN)
- Europe Market Estimate by Country (USD MN)
- United Kingdom Market Analysis (USD MN)
- France Market Analysis (USD MN)
- Germany Market Analysis (USD MN)
- Italy Market Analysis (USD MN)
- Russia Market Analysis (USD MN)
- Spain Market Analysis (USD MN)
- Rest of Europe Market Analysis (USD MN)
- Asia Pacific Market Analysis (USD MN)
- China Market Analysis (USD MN)
- Japan Market Analysis (USD MN)
- India Market Analysis (USD MN)
- South Korea Market Analysis (USD MN)
- Australia Market Analysis (USD MN)
- South East Asia Market Analysis (USD MN)
- Rest of Asia Pacific Market Analysis (USD MN)
- Latin America Market Analysis (USD MN)
- Brazil Market Analysis (USD MN)
- Argentina Market Analysis (USD MN)
- Peru Market Analysis (USD MN)
- Chile Market Analysis (USD MN)
- Rest of Latin America Market Analysis (USD MN)
- Middle East & Africa Market Analysis (USD MN)
- Saudi Arabia Market Analysis (USD MN)
- UAE Market Analysis (USD MN)
- Israel Market Analysis (USD MN)
- South Africa Market Analysis (USD MN)
- Rest of Middle East and Africa Market Analysis (USD MN)
- Partnership/Collaboration/Agreement
- Mergers And Acquisition
LIST OF FIGURES
- Research Scope of Lenalidomide Report
- Market Research Process
- Market Research Methodology
- Global Lenalidomide Market Size, by Region (USD MN)
- Porters Five Forces Analysis
- Market Attractiveness Analysis by Type
- Market Attractiveness Analysis by Application
- Market Attractiveness Analysis by End-User
- Market Attractiveness Analysis by Region
- Value Chain Analysis
- Global Market Analysis by Type (USD MN)
- 5mg Capsules Market Sales by Geography (USD MN)
- 10mg Capsules Market Sales by Geography (USD MN)
- 15mg Capsules Market Sales by Geography (USD MN)
- 25mg Capsules Market Sales by Geography (USD MN)
- Global Market Analysis by Application (USD MN)
- Multiple Myeloma (MM) Market Sales by Geography (USD MN)
- Myelodysplastic Syndromes (MDS) Market Sales by Geography (USD MN)
- Other Applications Market Sales by Geography (USD MN)
- Global Market Analysis by End-User (USD MN)
- Hospitals Market Sales by Geography (USD MN)
- Cancer Treatment Centers Market Sales by Geography (USD MN)
- Research Institutes Market Sales by Geography (USD MN)
- Global Market Sales (USD MN)
- North America Market Sales (USD MN)
- Europe Market Sales (USD MN)
- Asia Pacific Market Sales (USD MN)
- Latin America Market Sales (USD MN)
- Middle East & Africa Market Sales (USD MN)
- Recent Development in Industry
- Top Company Market Share Analysis
![来那度胺市场- 依类型（5mg、10mg、15mg、25mg 胶囊）、应用（多发性骨髓瘤[MM]、骨髓增生异常综合症[MDS]）、最终用户（医院、癌症治疗中心、研究机构） - 全球预测，2024 年 - 2032](/sample/img/cover/42/default_cover_0.png)
